Trial Profile
A clinical efficacy study of an oral tyrosine kinase inhibitor of VEGFR-2 given in combination with chemotherapy (paclitaxel and carboplatin) vs. chemotherapy alone for the treatment of advanced stage non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs PAN 90806 (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 10 Aug 2006 Status change
- 03 Oct 2005 New trial record.